StocksFundsScreenerSectorsWatchlists
SPRO

SPRO - Spero Therapeutics Inc Stock Price, Fair Value and News

1.69USD+0.01 (+0.60%)Market Closed

Market Summary

SPRO
USD1.69+0.01
Market Closed
0.60%

SPRO Stock Price

View Fullscreen

SPRO RSI Chart

SPRO Valuation

Market Cap

90.5M

Price/Earnings (Trailing)

-56.07

Price/Sales (Trailing)

0.87

Price/Free Cashflow

-2.74

SPRO Price/Sales (Trailing)

SPRO Profitability

Return on Equity

-1.51%

Return on Assets

-0.88%

Free Cashflow Yield

-36.46%

SPRO Fundamentals

SPRO Revenue

Revenue (TTM)

103.8M

Rev. Growth (Yr)

54.98%

Rev. Growth (Qtr)

188.63%

SPRO Earnings

Earnings (TTM)

-1.6M

Earnings Growth (Yr)

72.55%

Earnings Growth (Qtr)

73.1%

Breaking Down SPRO Revenue

52 Week Range

1.132.00
(Low)(High)

Last 7 days

-5.6%

Last 30 days

1.8%

Last 90 days

15.8%

Trailing 12 Months

11.9%

How does SPRO drawdown profile look like?

SPRO Financial Health

Current Ratio

3.53

SPRO Investor Care

Shares Dilution (1Y)

2.47%

Diluted EPS (TTM)

0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202353.5M54.2M77.7M103.8M
202213.0M9.9M8.8M53.5M
202114.9M18.4M17.4M18.3M
202012.1M11.7M11.1M9.3M
201910.5M12.2M16.2M18.1M
20183.0M3.2M3.3M4.0M
2017663.7K992.3K1.3M2.0M
2016000335.0K

Tracking the Latest Insider Buys and Sells of Spero Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 05, 2024
shukla sath
sold
-65,384
1.45
-45,093
ceo and president
Feb 02, 2024
shukla sath
sold
-42,334
1.37
-30,901
ceo and president
Feb 02, 2024
joseph tamara l
sold
-42,341
1.37
-30,906
chief legal officer
Feb 02, 2024
hamed kamal
sold
-38,462
1.37
-28,075
chief medical officer
Feb 02, 2024
mahadevia ankit
sold
-87,399
1.37
-63,795
-
Feb 02, 2024
keutzer timothy
sold
-42,120
1.36
-30,971
chief operating officer
Feb 01, 2024
hamed kamal
acquired
-
-
239,731
chief medical officer
Feb 01, 2024
rajavelu esther
acquired
-
-
119,866
see remarks
Feb 01, 2024
joseph tamara l
acquired
-
-
239,731
chief legal officer
Feb 01, 2024
keutzer timothy
acquired
-
-
239,731
chief operating officer

1–10 of 50

Which funds bought or sold SPRO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
5.53
531,632
2,416,320
-%
Feb 27, 2024
Beaird Harris Wealth Management, LLC
sold off
-100
-245
-
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
added
24.36
73,990
218,820
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
unchanged
-
3.00
18.00
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
35,048
198,156
-%
Feb 14, 2024
Royal Bank of Canada
added
5.00
-
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
47,442
47,442
-%
Feb 14, 2024
STATE STREET CORP
unchanged
-
33,933
191,851
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
reduced
-86.58
-34,623
6,747
-%

1–10 of 47

Are Funds Buying or Selling SPRO?

Are funds buying SPRO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SPRO
No. of Funds

Unveiling Spero Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
anson funds management lp
8.1%
4,297,599
SC 13G
Feb 14, 2023
biotechnology value fund l p
-
0
SC 13G/A
Feb 14, 2023
aquilo capital management, llc
0%
0
SC 13G/A
Jan 20, 2023
gsk plc
17.75%
9,190,606
SC 13D/A
Nov 14, 2022
gsk plc
19.99%
9,190,606
SC 13D/A
Oct 03, 2022
aquilo capital management, llc
3.6%
1,242,965
SC 13G/A
Jul 08, 2022
blackrock inc.
2.1%
690,753
SC 13G
Mar 09, 2022
aquilo capital management, llc
5.1%
1,642,655
SC 13G/A
Feb 14, 2022
aquilo capital management, llc
10.5%
3,378,881
SC 13G/A
Feb 14, 2022
biotechnology value fund l p
6.4%
2,169,102
SC 13G/A

Recent SEC filings of Spero Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 29, 2024
8-K
Current Report
Mar 22, 2024
EFFECT
EFFECT
Mar 15, 2024
S-3
S-3
Mar 15, 2024
S-8
Employee Benefits Plan
Mar 13, 2024
10-K
Annual Report
Mar 13, 2024
8-K
Current Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
8-K
Current Report
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Spero Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
2.01% -33.59%
-8.52
5.86
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.7B
1.8B
4.15% -26.04%
-44.64
10.75
76.23% 61.08%
16.5B
2.4B
1.55% -12.37%
98.23
6.81
15.42% 18.43%
12.4B
3.7B
-8.31% -27.12%
20.68
3.34
8.87% 75.42%
MID-CAP
6.5B
396.6M
-12.77% -31.76%
-12.27
16.36
425.83% 18.94%
5.0B
-
-2.52% 80.97%
-7.61
60.35
54.84% -34.79%
3.4B
270.6M
-2.48% 20.65%
-14.28
12.62
440.80% -27.84%
3.2B
240.7M
-23.17% -1.80%
-10.73
13.23
-1.03% -92.09%
2.9B
726.4M
-24.02% -2.94%
-47.86
4.04
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.62% -10.82%
25.58
4.59
85.90% -14.05%
620.0M
983.7M
-18.72% -47.64%
-1.14
0.63
-50.36% 17.16%
419.8M
881.7K
-10.95% 416.26%
-9.41
466.16
-77.61% -5.33%
264.3M
4.9M
11.10% 22.40%
-1.96
54.31
-54.97% 51.72%
7.9M
2.1M
91.53% 83.74%
-0.29
2.14
-13.45% 66.37%

Spero Therapeutics Inc News

Latest updates
Defense World05 Apr 202409:52 am
InvestorsObserver19 Mar 202411:29 am
Zacks Investment Research13 Mar 202408:23 pm
StockNews.com3 months ago

Spero Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue188.6%73,522,50025,473,0002,716,0002,069,00047,441,0002,006,0001,993,0002,069,0002,744,0003,064,0005,148,0007,300,0001,907,0003,995,0001,727,0001,701,0003,630,0004,643,0002,156,0007,718,0001,692,000
Operating Expenses-16.1%22,990,50027,407,00015,606,00016,296,00021,517,00013,840,00028,073,00032,276,00030,246,00025,588,00023,690,00026,703,00020,703,00023,015,00020,203,00024,522,00029,513,00022,628,00015,808,00013,414,00012,776,000
  S&GA Expenses12.7%6,433,0005,708,0006,096,0007,317,0006,495,0006,632,0008,051,00015,305,00013,021,00011,152,0009,229,0008,299,0007,498,0005,309,0004,547,0004,086,0003,785,0004,133,0003,782,0003,888,0003,649,000
  R&D Expenses1.0%16,557,50016,393,0009,510,0008,979,00015,089,0007,360,0008,173,00016,971,00017,225,00014,436,00014,461,00018,404,00013,205,00017,706,00015,656,00020,436,00025,728,00018,495,00012,026,0009,526,0009,127,000
EBITDA Margin--------9.02-6.84-4.88---5.19-8.30-5.47-5.14-4.96-3.31-2.51-3.36-3.91-
Income Taxes-82.5%387,0002,211,000-------------------
EBT Margin--------9.09-6.89-4.92---5.24-8.39-5.51-5.21-5.02-3.36-2.57-3.41-3.96-
Net Income100.0%--3,205,000-11,914,000-13,266,00026,771,000-11,675,000-28,682,000-32,829,000-29,240,000-22,521,000-18,572,000-19,423,000-18,585,000-18,936,000-17,501,000-23,258,000-24,986,000-17,717,000-13,150,000-5,072,000-10,599,000
Net Income Margin25.1%-0.02-0.02-0.19-0.50-0.87-11.62-11.48-7.92-4.92-4.54-4.12-4.99---------
Free Cashflow-209.9%-17,493,00015,915,000-18,564,000-12,853,00044,482,000-957,000-23,033,000-28,223,000-27,349,000-4,952,000-16,579,000-15,491,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets70.3%18210799.0011312564.0064.0014617114512014315315798.00110106113122125129
  Current Assets28.4%13110288.0010211453.0052.0013315813210612913914385.0098.0095.00104113116124
    Cash Equivalents-18.6%76.0094.0078.0096.0010950.0045.0072.0011311372.0077.0085.0012565.0064.0030.0046.0071.0049.0034.00
  Net PPE-95.1%0.000.000.000.000.000.001.001.001.001.001.002.002.002.002.002.002.003.003.003.003.00
Liabilities41.4%75.0053.0044.0048.0049.0032.0028.0083.0083.0033.0029.0025.0021.0024.0024.0027.0032.0019.0013.0011.0013.00
  Current Liabilities45.9%37.0025.0017.0023.0022.0016.0014.0069.0019.0017.0013.0018.0014.0018.0019.0023.0027.0015.008.007.0012.00
Shareholder's Equity99.0%10754.0055.0065.0076.0032.0036.0062.0088.0011290.0011913213374.0082.0075.0093.00110113116
  Retained Earnings11.6%-391-442-439-427-413-440-429-400-367-338-315-297-277-259-240-222-199-174-156-143-138
  Additional Paid-In Capital0.4%498496494492490473465463456450406416410392314305274267266257254
Shares Outstanding0.0%53.0053.0053.0053.0052.0034.0033.0033.0032.0030.0030.0029.00---------
Minority Interest------------------0.000.000.000.00
Float-----22.00-----326---256---151--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-209.9%-17,49315,915-18,564-12,85344,482-957-23,033-28,223-27,349-4,952-16,567-15,479-16,383-21,264-24,896-23,329-17,367-9,659-12,070-10,924-13,509
  Share Based Compensation4.7%1,9971,9081,8572,1702,4972,1061,3173,2032,9282,3302,1632,0091,3651,1991,2141,110929981933933769
Cashflow From Investing-------12950,000-16,064-23,27517,02510,9193,003-39,7403,94918,48527,776-4,099-15,88724,84524,6717,287
Cashflow From Financing-99.5%1.00220--14,1796,131-53,6773,81450,34929,2241684,30916,09077,2157,39030,1865,59910.008,9631,568-178

SPRO Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues:  
Grant revenue$ 7,046$ 4,930
Collaboration revenue - related party95,80246,076
Collaboration revenue$ 933$ 2,503
Type of Revenue [Extensible List]License [Member]License [Member]
Total revenues$ 103,781$ 53,509
Operating expenses:  
Research and development51,44047,593
General and administrative25,55436,483
Impairment of assets5,306635
Restructuring011,630
Total operating expenses82,30095,706
Income (loss) from operations21,481(42,197)
Other income (expense):  
Interest income3,9371,106
Other income (expense), net(14)(55)
Interest expense related to the sale of future royalties0(2,605)
Loss on extinguishment of liability related to the sale of future royalties0(3,581)
Change in fair value of derivative liability0917
Total other income (expense), net3,923(4,218)
Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net, Total25,404(46,415)
Income tax expense(2,598)0
Net income (loss)$ 22,806$ (46,415)
Net loss per share attributable to common stockholders, basic$ 0.43$ (1.23)
Net loss per share attributable to common stockholders, diluted$ 0.43$ (1.23)
Basic weighted average common shares outstanding52,703,46737,585,075
Weighted Average Number of Shares Outstanding, Diluted52,989,03037,585,075
Comprehensive income (loss):  
Net income (loss)$ (22,806)$ 46,415
Other comprehensive gain (loss):  
Unrealized gain on marketable securities02
Net unrealized gains (losses) on securities02
Total comprehensive income (loss)$ 22,806$ (46,413)

SPRO Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 76,333$ 109,107
Collaboration receivable, current - related party49,1520
Other receivables1,5451,084
Prepaid expenses and other current assets4,1783,379
Total current assets131,208113,570
Property and equipment, net2368
Collaboration receivable, non-current - related party46,5900
Operating lease right-of-use assets4,1555,124
Other assets4355,740
Total assets182,390124,802
Current liabilities:  
Accounts payable1,378617
Accrued expenses and other current liabilities6,5578,973
Operating lease liabilities1,7181,690
Income taxes payable3870
Deferred Revenue, Current2,1324,149
Deferred revenue, current - related party24,9816,220
Total current liabilities37,15321,649
Non-current operating lease liabilities3,8254,957
Deferred revenue, non-current10,8259,741
Deferred revenue, non-current - related party23,60612,425
Other long-term liabilities8796
Total liabilities75,49648,868
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 202200
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2023 and 2022; 52,999,680 shares issued and outstanding as of December 31, 2023 and 52,456,195 shares issued and outstanding as of December 31, 20225352
Additional paid-in capital497,913489,760
Accumulated deficit(391,072)(413,878)
Accumulated other comprehensive income (loss)00
Total stockholders' equity106,89475,934
Total liabilities and stockholders' equity$ 182,390$ 124,802
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://sperotherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES35

Spero Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Spero Therapeutics Inc? What does SPRO stand for in stocks?

SPRO is the stock ticker symbol of Spero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spero Therapeutics Inc (SPRO)?

As of Mon Apr 08 2024, market cap of Spero Therapeutics Inc is 90.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers. The fair value of Spero Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Spero Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SPRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Spero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SPRO is over valued or under valued. Whether Spero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Spero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRO.

What is Spero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 08 2024, SPRO's PE ratio (Price to Earnings) is -56.07 and Price to Sales (PS) ratio is 0.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRO PE ratio will change depending on the future growth rate expectations of investors.